QuantHealth raises $45M to simulate clinical trials before they run
What's the deal? QuantHealth, an Israeli startup that builds AI-based simulations for clinical trials, has raised $45 million in a Series B round led by growth fund Qumra CapitalDealroom has a profile for this one. Try Dealroom →. The round brings the company's total funding to $75 million.
Who else is in? Participants included Pitango HealthTechDealroom has a profile for this one. Try Dealroom →, Sanofi VenturesDealroom has a profile for this one. Try Dealroom →, Bertelsmann Healthcare InvestmentsDealroom has a profile for this one. Try Dealroom →, GC VenturesDealroom has a profile for this one. Try Dealroom →, NewHealth VenturesDealroom has a profile for this one. Try Dealroom →, Shoni Top VenturesDealroom has a profile for this one. Try Dealroom →, and Esplanade VenturesDealroom has a profile for this one. Try Dealroom →. Previous backers include pharmaceutical giant SanofiDealroom has a profile for this one. Try Dealroom → and Accenture VenturesDealroom has a profile for this one. Try Dealroom →.
What's the endgame? QuantHealth says its technology can help drugmakers test decisions before enrolling patients or spending billions on development. It has already simulated more than 600 trials.
Why now? Demand for modelling and simulation software is surging as AI promises to cut drug development costs and timelines, chief executive officer Orr Inbar told Axios.
The signal: This is a sizeable bet on a young market. The $45 million round sits in the top 10% of all Series B rounds raised by Israeli health companies, a sign of investor conviction that AI can reshape one of pharma's costliest bottlenecks.
Read more: calcalistech.com
Image credit: Generated with Gemini
